Featuring perspectives from Dr Arvind Dasari, Dr Christopher Lieu, Dr Van K Morris, Dr Jenny Seligmann and Prof Eric Van Cutsem, moderated by Dr Lieu, including the following topics:

• Introduction (0:00)
• Optimizing Biomarker Assessment for Patients with Colorectal Cancer (CRC) — Dr Dasari (2:18)
• Identification and Management of Metastatic CRC (mCRC) with a BRAF V600E Mutation — Dr Morris (26:37)
• Incorporation of Immune Checkpoint Inhibitors into the Management of Microsatellite Instability-High/Mismatch Repair-Deficient CRC — Dr Seligmann (49:46)
• Integration of Therapies Targeting HER2 into the Management of mCRC — Prof Van Cutsem (1:14:19)
• Biomarker-Based Decision-Making for Patients with mCRC and KRAS G12C Mutations — Dr Lieu (1:36:36)

CME information and select publications

Featuring an interview with Dr Surbhi Sidana, including the following topics:

• Long-term outcomes for patients with relapsed/refractory multiple myeloma (MM) (0:00)
• Clinical considerations in the selection of patients for chimeric antigen receptor (CAR) T-cell therapy (3:34)
• Practical challenges for patients receiving CAR T-cell therapy (8:34)
• Selection among available CAR T-cell therapies (12:18)
• Prevention, management and supportive care involved in the management of toxicities associated with CAR T-cell therapy (16:34)
• Secondary cancers associated with CAR T-cell therapy (21:25)
• Bridging therapy considerations for patients receiving CAR T-cell treatment (25:15)
• Utility of antibody-drug conjugates and bispecific antibodies for MM (27:49)
• Case: A man in his early 40s experiences rapid progression on induction therapy for MM (31:59)
• Case: A man in his early 50s with heavily pretreated MM receives multiple CAR T-cell therapies (41:47)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Surbhi Sidana, including the following topics:

• Key clinical data of FDA-approved chimeric antigen receptor (CAR) T-cell therapies (0:00)
• Real-world evidence evaluating utility of CAR T-cell therapies in the clinic (8:08)
• Impact of prior BCMA-targeted treatment on CAR T-cell therapy efficacy (12:55)
• Investigational CAR T-cell therapies in clinical development (15:08)
• Incidence and management of toxicities associated with CAR T-cell therapy (18:21)

CME information and select publications